Enzo Biochem, New York, has received FDA emergency use authorization for its covid-19 test kit. The test is intended for use on Enzo’s proprietary Genflex open diagnostic platform. Kits include a collection system as well as sample processing and molecular analytic components that address and circumvent the supply shortfalls currently affecting laboratories throughout the diagnostic community.
The test kits are part of Enzo’s comprehensive covid-19 program, which includes the company’s molecular diagnostic virus screening products, detection of immunity through IgG/IgM serological enzyme-linked immunosorbent assays (ELISAs), detection of inflammation on Enzo’s ELISA platform, and a promising proprietary drug candidate (SK1-I).

“Enzo is uniquely positioned to address the covid-19 pandemic from multiple angles,” says Elazar Rabbani, PhD, chief executive officer at Enzo. “We have an open molecular diagnostic system with complete capabilities from sample collection to processing, detection, and analytics. Our open system allows for adoptability with regard to reagents, supplies, and instruments. This system can be used for the current covid-19 crisis, and furthermore it can be repurposed for any current or future infectious agent diagnosis.

“Our solutions are available as full system product sales or as individual components,” Rabbani adds.“We have launched this platform, now available for purchase, and we are also processing tests at our Clinical Laboratory Improvement Amendments laboratory, where we have current capacity of 2,000 covid-19 molecular tests per day and can expand to meet market demand.”

For more information, visit Enzo Biochem.